BRCA1 Versus BRCA2 and PARP Inhibitor Sensitivity in Prostate Cancer: More Different Than Alike?

BRCA1 Versus BRCA2 and PARP Inhibitor Sensitivity in Prostate Cancer: More Different Than Alike? J Clin Oncol. 2020 Sep 01;:JCO2002246 Authors: Markowski MC, Antonarakis ES PMID: 32870734 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/32870734?dopt=Abstract

Source: Clinical Prostate Cancer - August 31, 2020 Category: Cancer & Oncology Authors: Markowski MC, Antonarakis ES Tags: J Clin Oncol Source Type: research

More News: Cancer | Cancer & Oncology | Prostate Cancer